Passage Bio Expands Leadership with New Board Appointment

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio, Inc. (Nasdaq: PASG), a pioneering company focused on developing genetic medicines aimed at addressing neurodegenerative diseases, is excited to announce the appointment of Tom Kassberg to its Board of Directors. Alongside his new position, Kassberg will also be a member of the Audit Committee, bringing significant expertise to the table.

Experience and Leadership Qualities of Tom Kassberg

Mr. Kassberg currently serves as the Chief Business Officer and Executive Vice President at Ultragenyx, a company dedicated to creating innovative therapies for rare genetic conditions. His extensive experience in business development and alliance management has been vital to advancing treatments, including several gene therapies in later-stage development. This background makes him an invaluable asset to Passage Bio during such a pivotal time for the organization.

Quotes from Leadership

Will Chou, M.D., president and CEO of Passage Bio, expressed the company's enthusiasm about this new appointment: "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission forward during this critical time for the organization. His deep understanding of strategic planning and corporate development makes him exceptionally well-equipped to guide Passage Bio as we pursue PBFT02 across several neurodegenerative indications. We're thrilled to have him join our team."

Kassberg’s Background in Biotechnology

Before joining Ultragenyx, Kassberg held an executive role at Proteolix, Inc. as the Executive Vice President of Corporate Development, where he spearheaded strategic initiatives and business development activities. Earlier in his career, he was the Senior Vice President of Corporate Development and Commercial Operations at InterMune, Inc. He co-founded Plexxikon and played a crucial role there, alongside significant contributions at SUGEN, where he was instrumental during its acquisition by Pharmacia. Mr. Kassberg’s journey began at Bristol Myers Squibb, where he honed his skills in strategic planning, sales, and financial analysis.

Vision for the Future

Mr. Kassberg conveyed his eagerness to be part of the Board, stating, "I am excited to join the Passage Bio Board of Directors and contribute to the continued growth of the company. The remarkable progress of the PBFT02 program and opportunity to expand into additional indications highlight Passage Bio’s dedication to making a critical impact in the field of neurodegenerative diseases. I look forward to collaborating with this exceptional team to drive forward our promising treatments and make a meaningful impact on the lives of patients and their families."

About Passage Bio

Passage Bio (Nasdaq: PASG) is at the forefront of genetic medicine, focusing on innovative therapies tailored for patients grappling with neurodegenerative diseases. The company’s mission is not just to develop treatments but to fundamentally enhance the quality of life for these patients. Its leading candidate, PBFT02, aims to treat conditions like frontotemporal dementia through innovative methodologies that restore lysosomal function and slow disease progression.

Passage Bio is dedicated to advancing its groundbreaking work while remaining steadfast in its commitment to patients and their families facing the devastating impact of neurodegenerative disorders. For more details about Passage Bio’s groundbreaking initiatives, you can visit www.passagebio.com.

Contact Information

For further inquiries, please reach out to:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com

Frequently Asked Questions

What role is Tom Kassberg taking at Passage Bio?

Tom Kassberg has been appointed to the Board of Directors and the Audit Committee at Passage Bio.

What is the primary focus of Passage Bio?

Passage Bio specializes in developing genetic medicines aimed at combating neurodegenerative diseases.

What is PBFT02?

PBFT02 is Passage Bio's leading product candidate designed to treat frontotemporal dementia by targeting underlying disease mechanisms.

What experience does Kassberg bring to Passage Bio?

Kassberg brings extensive experience in business development and corporate strategy from his previous roles at Ultragenyx and Proteolix, among others.

How can I find more information about Passage Bio?

More information about Passage Bio’s mission and projects can be found on their official website at www.passagebio.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.